This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong growth in membership, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity
by Zacks Equity Research
Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.
Community Health (CYH), Mindoula to Offer Mental Health Care
by Zacks Equity Research
Community Health (CYH) collaborates with Mindoula to enhance the availability of behavioral health resources to its affiliated provider network, who can now treat patients better.
Are Options Traders Betting on a Big Move in Alcon (ALC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.
3 MedTech Stocks to Bet on Potential Pause of Rate Hike by Fed
by Indrajit Bandyopadhyay
Interest rates impact the healthcare industry and medical device companies in various ways. Here we discuss three companies HCA, ALC and SEM that are likely to gain potential pause in rate hikes.
Centene (CNC) Divests Circle Health Group, Optimizes Portfolio
by Zacks Equity Research
Centene (CNC) announces the sale of Circle Health Group to PureHealth in a bid to dispose of non-core assets and grow its core Managed Care business.
Cigna (CI) Eases Care Delivery With Prior Authorization Removal
by Zacks Equity Research
Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.
Has Alcon (ALC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Time to Buy These Medical Stocks as Earnings Approach
by Shaun Pruitt
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.
Here's Why You Should Invest in Alcon (ALC) Stock Now
by Zacks Equity Research
Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.
Zacks Industry Outlook Highlights Alcon, Hologic and Penumbra
by Zacks Equity Research
Alcon, Hologic and Penumbra have been highlighted in this Industry Outlook article.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. ALC, HOLX and PEN are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.
Select Medical (SEM) Expects Q2 Adjusted EBITDA to Jump 21% Y/Y
by Zacks Equity Research
Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.
QIAGEN (QGEN) Expands Digital PCR Offering With New Pact
by Zacks Equity Research
QIAGEN (QGEN) and Niba Labs can assist companies developing cell and gene therapies to overcome significant resource limitations and adhere to stringent project deadlines.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
NextGen (NXGN) Settles Misrepresentation Allegations for $31M
by Zacks Equity Research
NextGen (NXGN) settles accusations of software fraud and anti-kickback violations for $31M. However, the company denies any wrongdoing.
Alcon (ALC) Gains From Robust Contact Lense Sales, Launches
by Zacks Equity Research
In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Boston Scientific (BSX) Gets FDA Nod for Vercise Software
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Neural Navigator 5 Software has an improved user interface that presents patient data in an easier-to-understand style and enables better therapy delivery.